MyFinsight
Home
Blog
About
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,094,300K
Free Cash flow
$408,000K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from borrowings, net
Proceeds from sales and maturiti...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Acquisition of apellis, net of c...
Repayments of borrowings
Purchases of marketable securiti...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
97,500
319,500
-48,900
466,500
Depreciation and amortization
236,100
204,400
200,200
202,200
Impairment of intangible assets
-
-
7,900
-
Impairment of rou asset
-
-
52,900
-
Impairment of intangible assets
-3,500
-
-
0
Excess and obsolescence charges related to inventory
5,100
4,800
15,300
-400
Amortization of acquired inventory step-up
202,800
107,600
75,400
61,500
Acquired in-process research and development
100,000
-
85,000
-
Share-based compensation
77,400
84,000
59,600
75,300
Contingent consideration
2,500
20,500
-62,000
5,600
Deferred income taxes
-27,600
23,600
166,900
253,800
(gain) loss on strategic investments
42,800
19,000
14,400
-500
Gain on sale of priority review voucher, net
-
-
0
0
Other
-36,000
-28,000
-19,000
-33,300
Accounts receivable-Nonrelated Party
132,300
108,600
-
-245,400
Accounts receivable-Related Party
91,600
-115,200
-
16,000
Inventory
-75,700
-116,200
29,400
7,400
Accrued expense and other current liabilities
-49,700
-243,200
203,800
286,000
Income tax assets and liabilities
13,800
18,400
-194,000
-229,400
Accounts receivable
-
-
-102,700
-
Other changes in operating assets and liabilities, net
-
-
-248,000
-
Other changes in operating assets and liabilities, net
54,000
89,000
-119,300
104,400
Net cash flow provided by (used in) operating activities
448,900
645,500
511,900
1,272,500
Purchases of property, plant and equipment
40,900
51,200
43,900
46,200
Proceeds from sales and maturities of marketable securities
1,515,200
625,200
23,000
-
Purchases of marketable securities
147,800
748,800
1,167,300
91,000
Acquisition, net of cash acquired-Reata Pharmaceuticals Inc
-
-
0
-
Acquisition of hi-bio, net of cash acquired
-
-
-
0
Acquisition, net of cash acquired-Hi Bio Acquisition
-
-
0
-
Proceeds from sales of strategic investments
-
-
56,700
0
Proceeds from sale of equity interest in samsung bioepis
-
-
0
-
Proceeds from sale of priority review voucher, net
-
-
0
0
Acquisition of apellis, net of cash acquired
5,065,100
-
-
-
Payments to acquire in process research and development
100,000
35,000
50,000
-
Acquisitions of intangible assets
0
0
16,300
5,300
Proceeds from sales of strategic investments
0
-56,100
-
56,600
Other
600
200
-22,700
-50,800
Net cash flow provided by (used in) investing activities
-3,839,200
-209,500
-1,231,700
-35,100
Payments related to issuance of stock for share-based compensation arrangements, net
-6,000
55,100
-3,000
-5,200
Proceeds from borrowings, net
2,400,000
-
0
-300
Repayments of borrowings
1,096,700
-
0
0
Net (distribution) contribution to noncontrolling interest
-
-
0
-
Contingent consideration payments
-
-
138,700
141,300
Other
-13,300
11,300
-1,300
6,200
Net cash flow provided by (used in) financing activities
1,296,000
-43,800
-137,000
-130,200
Net increase (decrease) in cash and cash equivalents
-2,094,300
392,200
-856,800
1,107,200
Effect of exchange rate changes on cash and cash equivalents
-3,400
-18,000
2,500
-3,200
Cash and cash equivalents, beginning of the period
3,382,700
3,008,500
2,598,300
2,598,300
Cash and cash equivalents, end of the period
1,285,000
3,382,700
3,008,500
3,862,800
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
borrowings, net
$2,400,000K
(38.46%↑ Y/Y)
Depreciation and
amortization
$236,100K
(21.51%↑ Y/Y)
Amortization of acquired
inventory step-up
$202,800K
(286.29%↑ Y/Y)
Acquired in-process
research and development
$100,000K
Payments related to
issuance of stock for...
-$6,000K
(1.64%↑ Y/Y)
Net income
$97,500K
(-84.64%↓ Y/Y)
Share-based compensation
$77,400K
(3.34%↑ Y/Y)
Inventory
-$75,700K
(-184.20%↓ Y/Y)
Other
-$36,000K
(-287.10%↓ Y/Y)
Income tax assets and
liabilities
$13,800K
(102.29%↑ Y/Y)
Excess and
obsolescence charges related...
$5,100K
(-27.14%↓ Y/Y)
Contingent consideration
$2,500K
(-81.06%↓ Y/Y)
Net cash flow
provided by (used in)...
$1,296,000K
(11176.92%↑ Y/Y)
Net cash flow
provided by (used in)...
$448,900K
(178.99%↑ Y/Y)
Canceled cashflow
$1,110,000K
Canceled cashflow
$401,500K
Net increase
(decrease) in cash and cash...
-$2,094,300K
(-2371.48%↓ Y/Y)
Canceled cashflow
$1,744,900K
Proceeds from sales and
maturities of marketable...
$1,515,200K
Repayments of borrowings
$1,096,700K
(-37.33%↓ Y/Y)
Other
-$13,300K
(-1008.33%↓ Y/Y)
Accounts
receivable-Nonrelated Party
$132,300K
(1360.00%↑ Y/Y)
Accounts
receivable-Related Party
$91,600K
(38.37%↑ Y/Y)
Other changes in
operating assets and...
$54,000K
(145.45%↑ Y/Y)
Accrued expense and
other current...
-$49,700K
(-173.08%↓ Y/Y)
(gain) loss on
strategic investments
$42,800K
(455.84%↑ Y/Y)
Deferred income taxes
-$27,600K
(11.82%↑ Y/Y)
Impairment of intangible
assets
-$3,500K
(-200.00%↓ Y/Y)
Net cash flow
provided by (used in)...
-$3,839,200K
(-6635.44%↓ Y/Y)
Canceled cashflow
$1,515,200K
Acquisition of apellis, net
of cash acquired
$5,065,100K
Purchases of marketable
securities
$147,800K
Payments to acquire in
process research and...
$100,000K
Purchases of property,
plant and equipment
$40,900K
(53.76%↑ Y/Y)
Other
$600K
(-98.03%↓ Y/Y)
Buy us a coffee